Senti Biosciences, Inc.

Developing smart cell and gene therapies with Gene Circuits to precisely target cancer.

SNTI | US

Overview

Corporate Details

ISIN(s):: US81726A1007
LEI:
Country:: United States of America
Address:: 2 CORPORATE DRIVE, FIRST FLOOR, 94080 SOUTH SAN FRANCISCO
Website:: https://www.sentibio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Senti Biosciences, Inc. is a clinical-stage biotechnology company developing a new generation of cell and gene therapies, referred to as "smarter medicines." The company's core technology is its proprietary Gene Circuit platform, which utilizes synthetic biology to reprogram cells with biological logic. These Gene Circuits are designed from novel DNA sequences to enable therapeutic cells to sense inputs, compute decisions, and respond to their specific cellular environments. Senti Bio's primary focus is on oncology, creating a pipeline of product candidates designed to precisely target and eliminate cancer cells while sparing healthy ones, aiming to provide potentially lifesaving treatments for patients with incurable diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Senti Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Senti Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Senti Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Eledon Pharmaceuticals, Inc. Develops immunomodulatory therapies to prevent organ rejection in transplant patients.	United States of America	ELDN
Elicera Therapeutics AB Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.	Sweden	ELIC
ELI LILLY & Co Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.	United States of America	LLY
Ellen AB Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.	Sweden	ELN
ELUTIA INC. Develops drug-eluting biologics to reduce complications from medical implants.	United States of America	ELUT
Emergent BioSolutions Inc. Develops and manufactures medical countermeasures for public health and national security threats.	United States of America	EBS
ENANTA PHARMACEUTICALS INC Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.	United States of America	ENTA
enGene Holdings Inc. Developing non-viral, locally administered gene therapies for rare genetic conditions.	United States of America	ENGN
Enliven Therapeutics, Inc. A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.	United States of America	ELVN
Enlivex Therapeutics Ltd. Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.	Israel	ENLV